“Safety And Efficacy Of Cisplatin Combined With Chemoradiotherapy In Locally Advanced Cervical Cancer Patients in Tertiary Care Hospital”
Keywords:
Cervical cancer, Cisplatin & Squamous cell carcinoma, Chemoradiotherapy
Abstract
Background: The number of cases of cervical cancer has increased in India during the previous year. Cervical cancer is a disease that causes morbidity and mortality worldwide. Cervical cancer patients progressed daily as a result of inadequate knowledge about the illness. Therefore, patient education is essential for both cervical cancer treatment and prevention. This research was done to find out if patients knew about the benefits and safety of combination chemotherapy and radiation therapy, or if they had any excuses for not getting their cervical cancer screened.
Objective:
- To evaluate the safety and efficacy of cisplatin in conjunction with radiation and chemotherapy for females suffering from locally advanced cervical cancer.
- To investigate the early outcome of cisplatin combined with chemotherapy and radiotherapy for cervical cancer patients.
Method: The study ran from October 2023 to April 2024 over the course of 7 month. There are a total number of 100 samples based on inclusion and exclusion criteria, patient data were collected. The quality of the data was evaluated by doing a database search for the safety and efficacy of cisplatin with chemotherapy in patients with locally advanced cervical cancer in Bihar using a questionnaire methodology.
Statistical analysis: All the data were recorded and analyzed. Statistics were carried out using SPSS software.
Results: This study involved 100 individuals in total. There are now 45 cases of people with cervical cancer. Twenty cases were eliminated from the study, leaving the remaining 25 cases eligible for inclusion based on the inclusion and exclusion criteria. The results of the trial showed that cisplatin and chemoradiotherapy are a safe and efficient combination for treating locally advanced cervical cancer.
Conclusion: Our study's results indicate that cisplatin in combination with radiation and chemotherapy is a tolerated and potentially better choice for treating patients with locally advanced cervical cancer. For the treatment of locally advanced cervical cancer, cisplatin and chemoradiotherapy may be given at the same time.
References
1. Cancer". World Health Organization. 12 September 2018. Retrieved 19 December 2018.
2. Defining Cancer". National Cancer Institute. 17 September 2007. Retrieved 28 March 2018.
3. World Health Organization, 2007. Ten statistical highlights in global public health. World health Statistics 2007. Geneva: World health Organization.
4. Marth C, Landoni F, Mahner S. “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of Oncology 2017;28(Suppl 4):iv72-iv83.
5. Ferlay J, Soerjomataram I, Dikshit R. “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012”.International Journal of Cancer 136:E359-E386, 2015.
6. Sudeep Gupta, AmitaMaheshwari, UmeshMahantshetty, “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer”, Journal Of Clinical Oncology, Volume 36 (16), 2018, 1543 – 1555.
7. National Comprehensive Cancer Network: Cervical Cancer (Version 1.2017-October 10, 2016).
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. “Global cancer statistics”. CA Cancer of Journal Clinical. 2011; 61:69–90.
9. Bray F, Ferlay J, Soerjomataram I. “Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA Cancer Journal Clinical. 2018.
10. ICO Information Centre on HPV and cancer. Human Papillomavirus and Related Diseases in India 2014- 2018;68:394–424.
11. Tracey E Schefter 1, Kathryn Winter, Janice S Kwon, “A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma”, Journal of Radiation Oncology Biologic Physics. 2012 Jul 15;83(4):1179-84
12. Achille Manirakiza, SumiSinha and Fidel Rubagumya. Locally Advanced Cervical Carcinoma Management, Cervical Cancer - Screening, Treatment and Prevention - Universal Protocols for Ultimate Control, Intech Open., 2018.
13. AswathySreedevi,ReshmaJaved, Avani Dinesh, “Epidemiology of cervical cancer with special focus on India”. International Journal of Women’s Health, 2015:7, 405 – 414.
14. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. “Risk factors and other epidemiologic considerations for cervical cancer screening, Annual Internal Medicine, 2011 Nov 15, volume 155,10:698-705
15. Arbyn M, Anttila A, Jordan A, Ronco G, Schenck U, Segnan N, Wiener H, Herbert H and vonKarsa L. “European Guidelines for Quality Assurance in Cervical Cancer Screening”. Annals of Oncology , 2010 , 21: 448–58.
16. National Comprehensive Cancer Center (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer, Version 2. 2013. Fort Washington, PA: NCCN; 2012.
17. Laurentius T, Altendorf-Hofmann A, Camara O, Runnebaum IB, Wendt TG. “Impact of age on morbidity and outcome of concurrent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery”. Journal of Cancer Research Clinical Oncology.2011;137(3):481–488.
18. Ikushima H, Osaki K, Furutani S, “Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiation Medicine. 2006;24(2):115–121
19. Hirakawa M, Nagai Y, Inamine M, Kamiyama K, Ogawa K, Toita T, “Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy”. Gynecology Oncology 2008; 108: 126–9.
20. Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, “The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy”. Cancer Oncology, 2013; 119: 325–31.
21. Hu Y, Cai ZQ, Su XY. “Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer”. Asian Pac Journal Cancer Prevention 2012; 13: 4301–4.
22. Yoshino Kinjyo, Yutaka Nagai, Md, TakafumiToita, “Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix, British Journal of Radiology , 2017; 90.
23. Nugent EK, Case AS, Hoff JT, “Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors”. Gynecology Oncology.2010;116(3):438–441
24. Yong-Fachen Wu-Bin Tang Xin-Xi Pan, “Safety and efficacy of nimotuzumab combined with chemoradiotherapy in chinese patients with locally advanced cervical cancer”, Oncology Targets and Therapy, 2017:10 4113–4119 39.
25. Viswanathan AN, Thomadsen B; “American Brachytherapy Society Cervical Cancer consensus guidelines for locally advanced carcinoma of the cervix”. General principles of Brachytherapy , 2012;11:33-46.
26. Gauravi A. Mishra Sharmila A. Pimple Surendra S. Shastri, “Prevention of Cervix Cancer in India, Oncology 2016;91(suppl 1):1–7.
27. Joshi S .Screening of cervical neoplasia in HIV-infected women in India. AIDS, 2013, 27(4): 607–615.
28. Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A. Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer, 2007; 109: 48 –53.
29. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. “Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma”.Gynecology Oncology. 2010;116:44–9.
30. Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. “Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta- analysis”. Gynecology Oncology ,2014;134:166-71.
31. King M, McConkey C, Latief TN, Hartley A, Fernando I. “Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side- effects”. Clinical Oncology,2006;18:38-45.
32. Cella D, Huang HQ, Monk BJ. “Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study”.GynecologOncology,2010;119:531.
33. Shyam Kishore Shrivastava, “Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial”. JAMA Oncology,.2018;4(4):506-513.
34. Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, Sukthomya V, Chakrabandhu S, Klunklin P. “Combined chemoradiation of cisplatin versus carboplatin in cervicalcarcinoma: a single institution experience from Thailand”. BMC Cancer. 2016;16:501-508.
35. Winter III WE, Maxwell GL, Tian C, SobelE, Scott Rose G, Thomas G. “Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy”. Gynecology Oncology.2004; 94(2)495-501.
36. Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K. “Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/ adenosquamous carcinoma versus squamous cell carcinoma”. Journal Gynecology Oncology. 2017;28(2):e19
37. Huang E, Lin H, Wang C, Chanchien C, Ou Y. “Impact of treatment time-related factor son prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer. Cancer Medicine. 2016;5(9):2205-12.
38. Ye Cao, Li Deng, Shixian Lian, Ying Jiang, “Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer”, JBUON 2019; 24(5): 2013-2019.
39. Zhan-Zhao Fu, Kun Li, Yong Peng, “Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer”, Medicine (2017) 96:2(e5853).
40. Fausto Petrelli , Agostina De Stefani, “Radiotherapy With Concurrent Cisplatin-Based Doublet or Weekly Cisplatin for Cervical Cancer”, Gynecology Oncology. 2014 Jul;134(1):166-71.
41. Bradley J. Monk, Michael W, “Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma”, Journal of Clinical Oncology, 2009, 27:4649-4655.
42. Tracey E Schefter 1, Kathryn Winter, Janice S Kwon, “A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma”, Journal of Radiation Oncology Biologic Physics. 2012 Jul 15;83(4):1179-84.
43. Fausto Petrelli , Agostina De Stefani , Francesco Raspagliesi , Domenica Lorusso , Sandro Barni , “Radiotherapy With Concurrent Cisplatin-Based Doublet or Weekly Cisplatin for Cervical Cancer”, Gynecology Oncology. 2014 Jul;134(1):166-167.
44. ShaloamDasari, Paul Bernard Tchounwou, “Cisplatin in cancer therapy: molecular mechanisms of action”, European Journal of Pharmacology, Volume 740, 5 , 2014, 364-378.
45. WataruKudaka, Yutaka Nagai, TakafumiToita, “Long-term results and prognostic factors in patients with stage III–IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study”, International Journal of Clinical Oncology ,(2013) 18:916–921.
46. Kimio Ushijima, KeizoFujiyoshi, Toshiharu Kamura. “Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer”, Journal of Gynecology Oncology, Vol. 24, No. 2:108-113.
47. KanyaratKatanyoo , SompolSanguanrungsirikul, SumonmalManusirivithaya, “Comparison of Treatment Outcomes Between Squamous Cell Carcinoma and Adenocarcinoma in Locally Advanced Cervical Cancer”, Gynecology Oncology. 2012 May;125(2):292-6.
48. Kenji Umayahara , MunetakaTakekuma , YasuyukiHirashima, “Phase II Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Patients With Locally Advanced Uterine Cervical Cancer”, Gynecology Oncology. 2016 Feb;140 (2):253-258.
2. Defining Cancer". National Cancer Institute. 17 September 2007. Retrieved 28 March 2018.
3. World Health Organization, 2007. Ten statistical highlights in global public health. World health Statistics 2007. Geneva: World health Organization.
4. Marth C, Landoni F, Mahner S. “Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Annals of Oncology 2017;28(Suppl 4):iv72-iv83.
5. Ferlay J, Soerjomataram I, Dikshit R. “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN2012”.International Journal of Cancer 136:E359-E386, 2015.
6. Sudeep Gupta, AmitaMaheshwari, UmeshMahantshetty, “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer”, Journal Of Clinical Oncology, Volume 36 (16), 2018, 1543 – 1555.
7. National Comprehensive Cancer Network: Cervical Cancer (Version 1.2017-October 10, 2016).
8. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. “Global cancer statistics”. CA Cancer of Journal Clinical. 2011; 61:69–90.
9. Bray F, Ferlay J, Soerjomataram I. “Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA Cancer Journal Clinical. 2018.
10. ICO Information Centre on HPV and cancer. Human Papillomavirus and Related Diseases in India 2014- 2018;68:394–424.
11. Tracey E Schefter 1, Kathryn Winter, Janice S Kwon, “A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma”, Journal of Radiation Oncology Biologic Physics. 2012 Jul 15;83(4):1179-84
12. Achille Manirakiza, SumiSinha and Fidel Rubagumya. Locally Advanced Cervical Carcinoma Management, Cervical Cancer - Screening, Treatment and Prevention - Universal Protocols for Ultimate Control, Intech Open., 2018.
13. AswathySreedevi,ReshmaJaved, Avani Dinesh, “Epidemiology of cervical cancer with special focus on India”. International Journal of Women’s Health, 2015:7, 405 – 414.
14. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. “Risk factors and other epidemiologic considerations for cervical cancer screening, Annual Internal Medicine, 2011 Nov 15, volume 155,10:698-705
15. Arbyn M, Anttila A, Jordan A, Ronco G, Schenck U, Segnan N, Wiener H, Herbert H and vonKarsa L. “European Guidelines for Quality Assurance in Cervical Cancer Screening”. Annals of Oncology , 2010 , 21: 448–58.
16. National Comprehensive Cancer Center (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer, Version 2. 2013. Fort Washington, PA: NCCN; 2012.
17. Laurentius T, Altendorf-Hofmann A, Camara O, Runnebaum IB, Wendt TG. “Impact of age on morbidity and outcome of concurrent radiochemotherapy in high-risk FIGO stage I to IVA carcinoma of the uterine cervix following laparoscopic surgery”. Journal of Cancer Research Clinical Oncology.2011;137(3):481–488.
18. Ikushima H, Osaki K, Furutani S, “Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiation Medicine. 2006;24(2):115–121
19. Hirakawa M, Nagai Y, Inamine M, Kamiyama K, Ogawa K, Toita T, “Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy”. Gynecology Oncology 2008; 108: 126–9.
20. Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, “The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy”. Cancer Oncology, 2013; 119: 325–31.
21. Hu Y, Cai ZQ, Su XY. “Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer”. Asian Pac Journal Cancer Prevention 2012; 13: 4301–4.
22. Yoshino Kinjyo, Yutaka Nagai, Md, TakafumiToita, “Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix, British Journal of Radiology , 2017; 90.
23. Nugent EK, Case AS, Hoff JT, “Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors”. Gynecology Oncology.2010;116(3):438–441
24. Yong-Fachen Wu-Bin Tang Xin-Xi Pan, “Safety and efficacy of nimotuzumab combined with chemoradiotherapy in chinese patients with locally advanced cervical cancer”, Oncology Targets and Therapy, 2017:10 4113–4119 39.
25. Viswanathan AN, Thomadsen B; “American Brachytherapy Society Cervical Cancer consensus guidelines for locally advanced carcinoma of the cervix”. General principles of Brachytherapy , 2012;11:33-46.
26. Gauravi A. Mishra Sharmila A. Pimple Surendra S. Shastri, “Prevention of Cervix Cancer in India, Oncology 2016;91(suppl 1):1–7.
27. Joshi S .Screening of cervical neoplasia in HIV-infected women in India. AIDS, 2013, 27(4): 607–615.
28. Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A. Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer, 2007; 109: 48 –53.
29. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. “Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma”.Gynecology Oncology. 2010;116:44–9.
30. Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. “Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta- analysis”. Gynecology Oncology ,2014;134:166-71.
31. King M, McConkey C, Latief TN, Hartley A, Fernando I. “Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side- effects”. Clinical Oncology,2006;18:38-45.
32. Cella D, Huang HQ, Monk BJ. “Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study”.GynecologOncology,2010;119:531.
33. Shyam Kishore Shrivastava, “Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial”. JAMA Oncology,.2018;4(4):506-513.
34. Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, Sukthomya V, Chakrabandhu S, Klunklin P. “Combined chemoradiation of cisplatin versus carboplatin in cervicalcarcinoma: a single institution experience from Thailand”. BMC Cancer. 2016;16:501-508.
35. Winter III WE, Maxwell GL, Tian C, SobelE, Scott Rose G, Thomas G. “Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy”. Gynecology Oncology.2004; 94(2)495-501.
36. Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K. “Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/ adenosquamous carcinoma versus squamous cell carcinoma”. Journal Gynecology Oncology. 2017;28(2):e19
37. Huang E, Lin H, Wang C, Chanchien C, Ou Y. “Impact of treatment time-related factor son prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer. Cancer Medicine. 2016;5(9):2205-12.
38. Ye Cao, Li Deng, Shixian Lian, Ying Jiang, “Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer”, JBUON 2019; 24(5): 2013-2019.
39. Zhan-Zhao Fu, Kun Li, Yong Peng, “Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer”, Medicine (2017) 96:2(e5853).
40. Fausto Petrelli , Agostina De Stefani, “Radiotherapy With Concurrent Cisplatin-Based Doublet or Weekly Cisplatin for Cervical Cancer”, Gynecology Oncology. 2014 Jul;134(1):166-71.
41. Bradley J. Monk, Michael W, “Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma”, Journal of Clinical Oncology, 2009, 27:4649-4655.
42. Tracey E Schefter 1, Kathryn Winter, Janice S Kwon, “A Phase II Study of Bevacizumab in Combination With Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients With Locally Advanced Cervical Carcinoma”, Journal of Radiation Oncology Biologic Physics. 2012 Jul 15;83(4):1179-84.
43. Fausto Petrelli , Agostina De Stefani , Francesco Raspagliesi , Domenica Lorusso , Sandro Barni , “Radiotherapy With Concurrent Cisplatin-Based Doublet or Weekly Cisplatin for Cervical Cancer”, Gynecology Oncology. 2014 Jul;134(1):166-167.
44. ShaloamDasari, Paul Bernard Tchounwou, “Cisplatin in cancer therapy: molecular mechanisms of action”, European Journal of Pharmacology, Volume 740, 5 , 2014, 364-378.
45. WataruKudaka, Yutaka Nagai, TakafumiToita, “Long-term results and prognostic factors in patients with stage III–IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study”, International Journal of Clinical Oncology ,(2013) 18:916–921.
46. Kimio Ushijima, KeizoFujiyoshi, Toshiharu Kamura. “Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer”, Journal of Gynecology Oncology, Vol. 24, No. 2:108-113.
47. KanyaratKatanyoo , SompolSanguanrungsirikul, SumonmalManusirivithaya, “Comparison of Treatment Outcomes Between Squamous Cell Carcinoma and Adenocarcinoma in Locally Advanced Cervical Cancer”, Gynecology Oncology. 2012 May;125(2):292-6.
48. Kenji Umayahara , MunetakaTakekuma , YasuyukiHirashima, “Phase II Study of Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Patients With Locally Advanced Uterine Cervical Cancer”, Gynecology Oncology. 2016 Feb;140 (2):253-258.
Published
2024-05-30
How to Cite
Seemu Singh, Sulekha, Sonam Chaturvedi, Pratibha Bhide, & Ankita Tiwari. (2024). “Safety And Efficacy Of Cisplatin Combined With Chemoradiotherapy In Locally Advanced Cervical Cancer Patients in Tertiary Care Hospital”. Revista Electronica De Veterinaria, 25(1S), 186-195. Retrieved from https://veterinaria.org/index.php/REDVET/article/view/597
Section
Articles
